PowerUp Acquisition (PWUP) Competitors $0.55 +0.01 (+1.66%) As of 08/22/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock PWUP vs. CMMB, LIXT, HOTH, NRSN, LSB, SYBX, ABP, LEXX, BLRX, and LPCNShould you be buying PowerUp Acquisition stock or one of its competitors? The main competitors of PowerUp Acquisition include Chemomab Therapeutics (CMMB), Lixte Biotechnology (LIXT), Hoth Therapeutics (HOTH), NeuroSense Therapeutics (NRSN), LakeShore Biopharma (LSB), Synlogic (SYBX), Abpro (ABP), Lexaria Bioscience (LEXX), BioLineRx (BLRX), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. PowerUp Acquisition vs. Its Competitors Chemomab Therapeutics Lixte Biotechnology Hoth Therapeutics NeuroSense Therapeutics LakeShore Biopharma Synlogic Abpro Lexaria Bioscience BioLineRx Lipocine Chemomab Therapeutics (NASDAQ:CMMB) and PowerUp Acquisition (NASDAQ:PWUP) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Do insiders & institutionals hold more shares of CMMB or PWUP? 46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 19.2% of PowerUp Acquisition shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 48.0% of PowerUp Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, CMMB or PWUP? Chemomab Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, PowerUp Acquisition has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Does the media refer more to CMMB or PWUP? In the previous week, Chemomab Therapeutics had 6 more articles in the media than PowerUp Acquisition. MarketBeat recorded 6 mentions for Chemomab Therapeutics and 0 mentions for PowerUp Acquisition. Chemomab Therapeutics' average media sentiment score of 0.92 beat PowerUp Acquisition's score of 0.00 indicating that Chemomab Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Chemomab Therapeutics Positive PowerUp Acquisition Neutral Is CMMB or PWUP more profitable? PowerUp Acquisition's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -94.71% -76.53% PowerUp Acquisition N/A N/A N/A Which has preferable earnings and valuation, CMMB or PWUP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$13.94M-$0.59-1.51PowerUp AcquisitionN/AN/AN/AN/AN/A Do analysts rate CMMB or PWUP? Chemomab Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 855.06%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Chemomab Therapeutics is more favorable than PowerUp Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00PowerUp Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryChemomab Therapeutics beats PowerUp Acquisition on 7 of the 10 factors compared between the two stocks. Get PowerUp Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for PWUP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PWUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PWUP vs. The Competition Export to ExcelMetricPowerUp AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$71.75M$247.21M$2.58B$9.76BDividend YieldN/A3.17%2.54%4.06%P/E RatioN/A0.1722.0426.05Price / SalesN/A520.92274.2388.42Price / CashN/A123.7024.1559.36Price / BookN/A8.3631.916.60Net IncomeN/A-$11.59M$31.01M$265.65M7 Day Performance52.12%5.53%1.09%2.00%1 Month Performance31.53%4.29%1.17%0.46%1 Year Performance-95.14%163.27%28.72%18.88% PowerUp Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PWUPPowerUp AcquisitionN/A$0.55+1.7%N/AN/A$71.75MN/A0.00N/AGap DownHigh Trading VolumeCMMBChemomab Therapeutics3.4836 of 5 stars$0.93-1.1%$8.50+814.0%-36.4%$17.73MN/A-1.5820News CoverageShort Interest ↓Analyst RevisionLIXTLixte Biotechnology0.0493 of 5 stars$3.48-8.9%N/A+89.4%$17.42MN/A-2.704HOTHHoth Therapeutics2.4541 of 5 stars$1.27-1.6%$4.00+215.0%+71.3%$17.10MN/A-1.194News CoveragePositive NewsAnalyst DowngradeShort Interest ↓NRSNNeuroSense Therapeutics2.3586 of 5 stars$1.16-7.2%$14.00+1,106.9%+41.3%$17.08MN/A-2.1510News CoverageShort Interest ↑LSBLakeShore Biopharma0.6231 of 5 stars$0.82flatN/A-81.4%$17.03M$85.67M0.00773SYBXSynlogicN/A$1.40-2.1%N/A-2.7%$16.73M$10K-0.5680Short Interest ↑Gap UpABPAbproN/A$0.25-8.1%$4.00+1,511.6%N/A$16.41M$180K0.0015LEXXLexaria Bioscience3.3701 of 5 stars$0.85+1.5%$4.00+371.1%-73.8%$16.36M$460K-1.277BLRXBioLineRx3.3871 of 5 stars$3.74-2.3%$26.00+595.2%-87.3%$16.33M$28.94M-0.4340LPCNLipocine2.4392 of 5 stars$2.96-1.7%$9.00+204.1%-15.3%$16.31M$11.20M-3.4010News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies CMMB Competitors LIXT Competitors HOTH Competitors NRSN Competitors LSB Competitors SYBX Competitors ABP Competitors LEXX Competitors BLRX Competitors LPCN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PWUP) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PowerUp Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share PowerUp Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access